Loading
KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate. The activation kinetics depend on the prepulse potential and external divalent cation concentration. With negative prepulses, the current activation is delayed and slowed down several fold, whereas more positive prepulses speed up activation.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.33, clinical 0.76).
In plain words · KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate.
No product in this corpus aims at KCNH1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNH1: RNA tissue enriched (brain 16 nTPM); high antibody staining in 6 normal tissues; highest cancer staining glioma (1 of 9 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNH1 tissue; Open Targets ENSG00000143473 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Occhiodoro et al, FEBS Lett, 1998, "Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion". Source.
Sources: HGNC HGNC:6250 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95259 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000143473 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0))
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents which, on depolarisation, reaches a steady-state level and do not inactivate. The activation kinetics depend on the prepulse potential and external divalent cation concentration. With negative prepulses, the current activation is delayed and slowed down several fold, whereas more positive prepulses speed up activation. The time course of activation is biphasic with a fast and a slowly activating current component. Activates at more positive membrane potentials and exhibit a steeper activation curve. Channel properties are modulated by subunit assembly. Location: Cell membrane; Nucleus inner membrane; Cell projection, dendrite; Cell projection, axon (UniProt). Locus 1q32.2 (HGNC).
RNA: tissue enriched (brain 16 nTPM), detected in some normal tissues.
Medium: Appendix, Cerebellum, Testis.
RNA cancer enhanced: Breast Invasive Carcinoma 2 pTPM.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNH1" OR ABSTRACT:"KCNH1" OR TITLE:"potassium voltage-gated channel subfamily H member 1" OR ABSTRACT:"potassium voltage-gated channel subfamily H member 1" OR TITLE:"Voltage-gated delayed rectifier potassium channel KCNH1" OR ABSTRACT:"Voltage-gated delayed rectifier potassium channel KCNH1" OR TITLE:"Kv10.1" OR ABSTRACT:"Kv10.1" OR TITLE:"eag" OR ABSTRACT:"eag" OR TITLE:"h-eag" OR ABSTRACT:"h-eag") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNH1, not a curated reading list.